Dopamine

Brain Wafers™ Offer Novel Path to Increase Neurotransmitters for Brain and Body Energy

Thursday, October 14, 2021 - 1:38pm

Offering on-the-go energy for brain and body, Brain Wafers have natural ingredients that enhance the body's own production of excitatory neurotransmitters safely increasing mental and physical energy, along with providing mood and memory support.

Key Points: 
  • Offering on-the-go energy for brain and body, Brain Wafers have natural ingredients that enhance the body's own production of excitatory neurotransmitters safely increasing mental and physical energy, along with providing mood and memory support.
  • Neurotransmitters are natural brain chemicals that help transmit nerve impulses to other nerves and organs, often classified as either stimulating or inhibiting.
  • Brain Wafers have natural precursors for aiding the body in creating these neurotransmitters.
  • Nutrients from Brain Wafers are quickly and efficiently absorbed and used, giving a needed energy lift that starts in minutes."

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

Wednesday, October 6, 2021 - 2:03pm

The Phase 2 KET-LID clinical trial is a randomized, double-blind, active placebo-controlled study evaluating the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinsons disease.

Key Points: 
  • The Phase 2 KET-LID clinical trial is a randomized, double-blind, active placebo-controlled study evaluating the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinsons disease.
  • Clinical trial drug product (ketamine) and active placebo (midazolam) have also been obtained.
  • Initiation of the Phase 2 clinical trial of ketamine to treat Parkinsons disease, or the KET-LID trial, is a significant milestone for PharmaTher and we are excited about the opportunity to advance a potential new therapeutic solution for Parkinsons disease patients, said Fabio Chianelli, CEO of PharmaTher.
  • PharmaTher is currently initiating an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

Monday, October 4, 2021 - 2:04pm

The Company will also present a poster review of patient-level data up to 24 months from the Phase 1/2 study of AXO-Lenti-PD gene therapy for the treatment of Parkinsons disease.

Key Points: 
  • The Company will also present a poster review of patient-level data up to 24 months from the Phase 1/2 study of AXO-Lenti-PD gene therapy for the treatment of Parkinsons disease.
  • The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease as well.
  • Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinsons disease, which affects millions of patients globally.

Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

Monday, October 4, 2021 - 12:30pm

The Company will also present a poster review of patient-level data up to 24 months from the Phase 1/2 study of AXO-Lenti-PD gene therapy for the treatment of Parkinsons disease.

Key Points: 
  • The Company will also present a poster review of patient-level data up to 24 months from the Phase 1/2 study of AXO-Lenti-PD gene therapy for the treatment of Parkinsons disease.
  • The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease as well.
  • Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
  • We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinsons disease, which affects millions of patients globally.

Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards

Friday, October 1, 2021 - 2:15pm

This years UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories.

Key Points: 
  • This years UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories.
  • Adamas developed GOCOVRI to make everyday life significantly better for people with Parkinsons disease, said Neil F. McFarlane, Chief Executive Officer.
  • It is, therefore, an honor to be selected as a finalist in a category recognizing the real impact innovative therapeutics can have on patients.
  • Id like to thank the Adamas team for their contributions which have enabled this recognition.

MiZ Company Limited Publishes Review Article on Discovery of Diatomic Molecule That Overcomes Diseases Caused by Chronic Inflammation, Incurable by Modern Medicine

Wednesday, September 29, 2021 - 8:00am

The prolonged state of chronic inflammation is called "Mibyou" in Oriental medicine, but modern medicine has no means to cure Mibyou.

Key Points: 
  • The prolonged state of chronic inflammation is called "Mibyou" in Oriental medicine, but modern medicine has no means to cure Mibyou.
  • MiZ Co., Ltd. has recently discovered a method to suppress this chronic inflammation and has published a comprehensive review.
  • In modern medicine, a typical example of an undiagnosed disease is an inflammatory disease caused by chronic inflammation.
  • MiZ Co., Ltd. focused on molecular hydrogen as a molecule that has the potential to cure diseases caused by chronic inflammation.

Global Animal Sedative Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Monday, September 27, 2021 - 10:14am

They are employed as tranquilizers, preanesthetic drugs, antiemetics, and for the treatment of CNS agitation in domestic animals.

Key Points: 
  • They are employed as tranquilizers, preanesthetic drugs, antiemetics, and for the treatment of CNS agitation in domestic animals.
  • The animals are provided sedative drugs for their cure from zoonoses, phenothiazines being the parent ingredient for the most regularly used sedative drugs.
  • Hence, the increase in the demand of this segment will drive the overall animal sedative market.
  • This, together with the rising frequency of animal diseases, will help this region maintain its market dominance in the years ahead.

PRAMASH BIKES Announces Kickstarter Campaign for Vinci, an Electric Bike

Thursday, September 23, 2021 - 3:00pm

The Vinci also has alloywheels and a color LCD display.All these functions with beautifuldesigns are available just for $1,250 on the Kickstarter campaign.

Key Points: 
  • The Vinci also has alloywheels and a color LCD display.All these functions with beautifuldesigns are available just for $1,250 on the Kickstarter campaign.
  • This is a deal-breaker when the Vinci bike is compared with other electric bikes available on the market with similar or fewer options for a lot higher price.
  • But most of these electric bikesare regular bicyclesoran old 1970sBonanza minibikeframethat hasslapped electronics on them, and these bikes arevery expensive.
  • The Vinci bike is designed byan artist and engineerand, when that combination happens,you get something attractive and functional.The Vinci bikesatisfies requirements of style and comfort.

Nurofen Teams up With Experts to Create Bespoke Music Track Shown to Reduce Pain Intensity

Wednesday, September 22, 2021 - 5:25pm

SLOUGH, United Kingdom, Sept. 22, 2021 /PRNewswire/ -- Pain relief experts Nurofen have partnered with experts to create a bespoke music track that reduced pain intensity and pain unpleasantness in a statistically and clinically significant way when tested. The Tune Out Pain project brought together the worlds of science, pain and music in a study led by Dr Claire Howlin, Psychology Researcher, University College Dublin who partnered with music producer, Anatole, (aka Jonathan Baker) a conservatory-trained trumpeter and multi-instrumentalist to compose the track.

Key Points: 
  • All Of Us was shown to reduce levels of pain intensity and unpleasantness in a way that was clinically and statistically significant.
  • Participants with different types of acute pain such as headache, backache or period pain reported their levels of pain intensity decreasing while listening to the track during the study.
  • Music and pain is something all of us experience this project shows how powerful music is and the potential benefit to our wellbeing."
  • The Tune Out Pain study tested the specially designed and composed track among 286 active acute pain sufferers in an online experiment.

Digbi Health AI Powered Digital Therapeutics Platform for Polychronic Illnesses Expands to Manage Mental Health

Tuesday, September 21, 2021 - 12:00pm

MOUNTAIN VIEW, Calif., Sept. 21, 2021 /PRNewswire/ -- Digbi Health , an AI-powered, precision digital therapeutics platform that uses gut microbiome and host genetic information, expands its digital health platform to manage several mental health and psychiatric disorders under the FDA's Enforcement Policy for Digital Health Devices For Treating Psychiatric Disorders during the Coronavirus Public Health Emergency.

Key Points: 
  • MOUNTAIN VIEW, Calif., Sept. 21, 2021 /PRNewswire/ -- Digbi Health , an AI-powered, precision digital therapeutics platform that uses gut microbiome and host genetic information, expands its digital health platform to manage several mental health and psychiatric disorders under the FDA's Enforcement Policy for Digital Health Devices For Treating Psychiatric Disorders during the Coronavirus Public Health Emergency.
  • Digbi Mental Health was created to improve the mental health and well-being of members during periods of shelter-in-place, isolation and quarantine and serves as an adjunct to clinician-supervised, outpatient treatment to its members.
  • A real world study of 275 Digbi Health members reveals clinically significant reductions in Anxiety, Insomnia & Depression symptoms linked to improved gut health.
  • Available on the Blue Shield of California Wellvolution platform, Digbi Cares is a next-generation, prescription-grade digital therapeutic platform, polychronic mental and physical illness.